SBF2 and breast carcinoma: To this end, we are conducting an NCI-sponsored ECOG-ACRIN clinical trial, EAZ171 (NCT04001829), to prospectively test whether breast cancer patients of African descent with germline SBF2 mutations do indeed have higher rates of TIPN.